What's Happening?
Biogen, in partnership with Ionis Pharmaceuticals, has presented promising data from its Phase 2 CELIA study on diranersen, an investigational antisense oligonucleotide therapy targeting tau in early Alzheimer's disease. The study, presented at the Alzheimer's Association
International Conference 2026, demonstrated significant clinical outcomes and robust reductions in tau levels. Diranersen showed efficacy across all studied doses over 18 months, with the 60 mg dose showing the strongest response. The drug achieved a 42% improvement on the ADAS-Cog13 cognitive scale and a 50% improvement on the MMSE scale. Additionally, diranersen reduced cerebrospinal fluid total tau by 50-65% and brain tau pathology as measured by PET scans. The study did not meet its primary endpoint of dose response on the CDR-SB scale, but the results support further development into Phase 3 trials.
Why It's Important?
The development of diranersen is significant as it represents a potential breakthrough in Alzheimer's treatment, particularly in targeting tau, a protein associated with neurodegenerative diseases. The positive results from the Phase 2 study suggest that diranersen could slow cognitive decline in patients with early Alzheimer's, offering hope for a condition with limited treatment options. The advancement of diranersen into Phase 3 trials could pave the way for a new class of Alzheimer's therapies, potentially benefiting millions of patients and impacting the healthcare industry by providing a novel approach to managing Alzheimer's disease.
What's Next?
Biogen plans to advance diranersen into confirmatory Phase 3 development, which will further evaluate its efficacy and safety in a larger patient population. The ongoing long-term extension study will continue to assess the drug's long-term safety and clinical benefits. If successful, diranersen could receive regulatory approval, providing a new treatment option for early Alzheimer's disease. The results of the Phase 3 trials will be crucial in determining the drug's future and its potential impact on Alzheimer's treatment protocols.
